Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05163080
Title SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE) (SURVIVE)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors MimiVax, LLC
Indications

glioblastoma

Therapies

SurVaxM + Temozolomide

Montanide ISA 51 + Sargramostim + SurVaxM + Temozolomide

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.